Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation

BACKGROUND: Dyslipidemia may be an important modifiable risk factor contributing to the increased cardiovascular risk in inflammatory bowel disease (IBD). The lipid metabolism is subject to both systemic inflammation and drug therapy; however, it is unclear if this effect is drug-class dependent. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Sleutjes, Jasmijn A M, Roeters van Lennep, Jeanine E, van der Woude, C Janneke, de Vries, Annemarie C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069657/
https://www.ncbi.nlm.nih.gov/pubmed/35590447
http://dx.doi.org/10.1093/ibd/izac100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069657/
https://www.ncbi.nlm.nih.gov/pubmed/35590447
http://dx.doi.org/10.1093/ibd/izac100

Ejemplares similares